A novel carbon monoxide-releasing molecule fully protects mice from severe malaria

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1281-1290

  Pena, Ana C ^a   Penacho, Nuno ^b   Mancio Silva, Liliana ^a   Neres, Rita ^a   Seixas, João D ^b,c   Fernandes, Afonso C ^a   Romão, Carlos C ^b,c   Mota, Maria M ^a   Bernardes, Gonçalo J L ^b,d   Pamplona, Ana ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b Alfama Lda   (Portugal)

^c INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^d ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALF 492; ANTIMALARIAL AGENT; ARTESUNATE; CARBON MONOXIDE; HEME OXYGENASE 1; HEMOGLOBIN; TRICARBONYLDICHLORO(THIOGALACTOPYRANOSIDE)RUTHENIUM II; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; BRAIN MALARIA; BRAIN PROTECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SYNTHESIS; IN VIVO STUDY; MOUSE; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE LUNG INJURY; ANIMALS; ANTIMALARIALS; CARBON MONOXIDE; CARBOXYHEMOGLOBIN; GENE EXPRESSION REGULATION; HEME OXYGENASE-1; HUMANS; MALARIA, CEREBRAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; ORGANOMETALLIC COMPOUNDS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; SEVERITY OF ILLNESS INDEX; THIOGALACTOSIDES;

EID: 84857153465     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05571-11     Document Type: Article

References (47)

1. Alcaraz MJ, Guillen MI, Ferrandiz ML, Megias J, Motterlini R. 2008. Carbon monoxide-releasing molecules: a pharmacological expedient to counteract inflammation. Curr. Pharm. Des. 14:465-472. (Pubitemid 351516851)
2. Baptista FG, et al. 2010. Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice. Infect. Immun. 78:4033-4039.
3. Belnoue E, et al. 2002. On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. J. Immunol. 169:6369-6375. (Pubitemid 36903485)
4. Berendt AR, Tumer GD, Newbold CI. 1994. Cerebral malaria: the sequestration hypothesis. Parasitol. Today 10:412-414. (Pubitemid 24306851)
5. Bernardes GJL, et al. 2010. Design, synthesis and biological evaluation of carbohydrate-functionalized cyclodextrins and liposomes for hepatocytespecific targeting. Org. Biomol. Chem. 8:4987-4996.
6. Bienvenu AL, Ferrandiz J, Kaiser K, Latour C, Picot S. 2008. Artesunate-erythropoietin combination for murine cerebral malaria treatment. Acta Trop. 106:104-108.
7. Canfield RE. 1963. The amino acid sequence of egg white lysozyme. J. Biol. Chem. 238:2698-2707.
8. Chen B, et al. 2009. Carbon monoxide rescues heme oxygenase-1-deficient mice from arterial thrombosis in allogeneic aortic transplantation. Am. J. Pathol. 175:422-429.
9. Clark JE, et al. 2003. Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. Circ. Res. 93:e2-e8.
10. de Kossodo S, Grau GE. 1993. Profiles of cytokine production in relation with susceptibility to cerebral malaria. J. Immunol. 151:4811-4820. (Pubitemid 23318534)
11. Epiphanio S, et al. 2010. VEGF promotes malaria-associated acute lung injury in mice. PLoS Pathog. 6:e1000916.
12. Favre N, et al. 1999. Role of ICAM-1 (CD54) in the development of murine cerebral malaria. Microbes Infect. 1:961-968.
13. Franke-Fayard B, Fonager J, Braks A, Khan SM, Janse CJ. 2010. Sequestration and tissue accumulation of human malaria parasites: can we learn anything from rodent models of malaria? PLoS Pathog. 6:e1001032.
14. Franke-Fayard B, et al. 2004. A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol. Biochem. Parasitol. 137:23-33. (Pubitemid 38987939)
15. Franklin BS, et al. 2011. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc. Natl. Acad. Sci. U. S. A. 108:3689-3694.
16. Gottschaldt M, Schubert US. 2009. Prospects of metal complexes peripherally substituted with sugars in biomedicinal applications. Chem. Eur. J. 15:1548-1557.
17. Hayashi S, et al. 1999. Induction of heme oxygenase-1 suppresses venular leukocyte adhesion elicited by oxidative stress: role of bilirubin generated by the enzyme. Circ. Res. 85:663-671. (Pubitemid 29480806)
18. Hegazi RA, et al. 2005. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J. Exp. Med. 202: 1703-1713. (Pubitemid 41815876)
19. Idro R, Jenkins NE, Newton CR. 2005. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 4:827-840. (Pubitemid 41619438)
20. Jain R, DalNogare A. 2006. Pharmacological therapy for acute respiratory distress syndrome. Mayo Clin. Proc. 81:205-212. (Pubitemid 43205775)
21. John CC, Kutamba E, Mugarura K, Opoka RO. 2010. Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. Expert Rev. Anti Infect. Ther. 8:997-1008.
22. Kim HP, Ryter SW, Choi AM. 2006. CO as a cellular signaling molecule. Annu. Rev. Pharmacol. Toxicol. 46:411-449. (Pubitemid 43271196)
23. Langhorne J, et al. 2011. The relevance of non-human primate and rodent malaria models for humans. Malar. J. 10:23.
24. Lee TS, Chau LY. 2002. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat. Med. 8:240-246.
25. Lunney J, Ashwell G. 1976. A hepatic receptor of avian origin capable of binding specifically modified glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 73:341-343.
26. Medana IM, Turner GD. 2006. Human cerebral malaria and the bloodbrain barrier. Int. J. Parasitol. 36:555-568. (Pubitemid 43674514)
27. Mishra SK, Newton CR. 2009. Diagnosis and management of the neurological complications of falciparum malaria. Nat. Rev. Neurol. 5:189-198.
28. Motterlini R, Otterbein LE. 2010. The therapeutic potential of carbon monoxide. Nat. Rev. Drug Discov. 9:728-743.
29. Mwangi TW, Ross A, Snow RW, Marsh K. 2005. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J. Infect. Dis. 191:1932-1939. (Pubitemid 40705402)
30. Neill AL, Hunt NH. 1992. Pathology of fatal and resolving Plasmodium berghei cerebral malaria in mice. Parasitology 105(Pt 2):165-175.
31. Nemeth E, Baird AW, O'Farrelly C. 2009. Microanatomy of the liver immune system. Semin. Immunopathol. 31:333-343.
32. Pamplona A, et al. 2007. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat. Med. 13: 703-710. (Pubitemid 46889755)
33. Rudin W, Favre N, Bordmann G, Ryffel B. 1997. Interferon-gamma is essential for the development of cerebral malaria. Eur. J. Immunol. 27: 810-815. (Pubitemid 27153646)
34. Sachs JD. 2002. A new global effort to control malaria. Science 298:122-124.
35. Santos-Silva T, et al. 2011. CORM-3 reactivity toward proteins: the crystal structure of a Ru(II) dicarbonyl-lysozyme complex. J. Am. Chem. Soc. 133:1192-1195.
36. Santos-Silva T, et al. 2011. Towards improved therapeutic CORMs: understanding the reactivity of CORM-3 with proteins. Curr. Med. Chem. 18:3361-3366.
37. Sinclair D, Donegan S, Lalloo DG. 2011. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst. Rev. 3:CD005967.
38. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48:1803-1806. (Pubitemid 38544392)
39. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214-217. (Pubitemid 40388051)
40. Thumwood CM, Hunt NH, Clark IA, Cowden WB. 1988. Breakdown of the blood-brain barrier in murine cerebral malaria. Parasitology 96(Pt 3):579-589.
41. Trampuz A, Jereb M, Muzlovic I, Prabhu RM. 2003. Clinical review: severe malaria. Crit. Care 7:315-323. (Pubitemid 36939551)
42. van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE. 2006. A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. Trends Parasitol. 22:503-508. (Pubitemid 44479847)
43. Veros CT, Oldham NJ. 2007. Quantitative determination of lysozyme-ligand binding in the solution and gas phases by electrospray ionisation mass spectrometry. Rapid Commun. Mass Spectrom. 21:3505-3510. (Pubitemid 350033331)
44. Vivas L, et al. 2008. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 105:222-228.
45. Vreman HJ, Wong RJ, Kadotani T, Stevenson DK. 2005. Determination of carbon monoxide (CO) in rodent tissue: effect of heme administration and environmental CO exposure. Anal. Biochem. 341:280-289. (Pubitemid 40724813)
46. WHO. 2008. World malaria report 2008. WHO, Geneva, Switzerland.
47. Wu J, Nantz MH, Zern MA. 2002. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front. Biosci. 7:d717-d725.